Journal of Clinical Immunology

, Volume 3, Issue 4, pp 295–315 | Cite as

Regulation of the immune response by prostaglandins

  • James S. Goodwin
  • Jan Ceuppens
Special Article


Of all the arachidonic acid metabolites, only prostaglandin E (PGE) has been shown to have a clear role in the regulation of cellular and humoral immune responses. In cellular immune responses such as T cell proliferation, lymphokine production, and cytotoxicity, PGE usually acts as a feedback inhibor of the response. This is also true of macrophage and natural killer cytotoxicity. In some instances PGE is responsible for cellular activation rather than inhibition. This is clearest in the control of humoral immunity, where PGE production is a necessary component in the generation of some type of T suppressor cells. Disturbances in immune function found in several human conditions and diseases have been linked to changes in PGE mediated immunoregulation. Either increased production of PGE or increased sensitivity to PGE results in depressed cellular immunity. Conversely drugs which inhibit PGE production act as stimulants of cellular immune functionin vitro andin vivo.

Key words

Prostaglandin E immune response suppressor cells cellular immunity humoral immunity immunoregulation non steroidal anti inflammatory agents 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parker CW: Prostaglandins and slow-reacting substance. J Allergy Clin Immunol 63:1–6, 1979Google Scholar
  2. 2.
    Lum GM, Aisenbrey GA, Dunn MJ, Berl RW, Schrier RW, McDonald KM: In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin. J Clin Invest 59:8–12, 1977Google Scholar
  3. 3.
    Trang LE: Prostaglandins and inflammation. Sem Arch Rheum 9:153–159, 1980Google Scholar
  4. 4.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231:231–238, 1971Google Scholar
  5. 5.
    Zurier RB, Quagliata F: Effect of prostaglandin E1 on adjuvant arthritis. Nature 234:304–310, 1971Google Scholar
  6. 6.
    Hurd ER, Johnston JM, Okita JR, MacDonald PC, Ziff M, Gilliam JW: Prevention of glomerulonephritis and prolonged survival in New Zealand black/New Zealand white F1 hybrid mice fed an essential fatty-acid deficient diet. J Clin Invest 67:476–482, 1981Google Scholar
  7. 7.
    Izui S, Kelley VE, McConahey PJ, Dixon FJ: Selective suppression of retroviral gp70- anti-gp70 immune complex formation by prostaglandin E1 in murine systemic lupus erythematosus. J Exp Med 152:1645–1653, 1980Google Scholar
  8. 8.
    Kelley VE, Windelstein A: Age- and sex-related glomerulonephritis in New Zealand white mice. Clin Immunol Immunopathol 16:142–148, 1980Google Scholar
  9. 9.
    McLeish KR, Gohara AF, Gunning WT, Senitzer D: Prostaglandin E1 therapy of murine chronic serum sickness. J Lab Clin Med 96:470–478, 1980Google Scholar
  10. 10.
    Zurier RB, Damjanov I, Sayadoff DM, Rothfield NF: Prostaglandin E, treatment of NZB/NZW F, hybrid mice. Arch Rheum 20:1449–1455, 1977Google Scholar
  11. 11.
    Zurier RB, Sayadoff DM, Torrey AB, Rothfield NF: Prostaglandin E treatment of NZB/NZW mice. Arth Rheum 20:723–730, 1977Google Scholar
  12. 12.
    Levin RI, Jaffe EA, Weksler BB, Tack-Goldman K: Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. J Clin Invest 67:762–770, 1981Google Scholar
  13. 13.
    Needleman P, Raz A, Ferrendelli JA, Minkes M: Application of imidazole as a selective inhibitor thromboxane synathetase in human platelets. Proc Natl Acad Sci 74:1716–1724, 1977Google Scholar
  14. 14.
    Gorman RR, Bundy GL, Peterson DC, Sun FF, Miller OV, Fitzpatrick FA: Inhibition of human platelet thromboxane synthetase by 9, 11-azoprosta-5,13-dienoic acid. Proc Natl Acad Sci 74:4007–4013, 1977Google Scholar
  15. 15.
    Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR: Arterial walls are protected against deposition of platelet thrombic by a substance (prostaglandin x) which they make from prostaglandin endoperoxides. Prostaglandins 12:685–691, 1976Google Scholar
  16. 16.
    Kantor HS, Hampton M: Indomethacin in submicromolar concentrations inhibits cyclic AMP-dependent protein kinase. Nature (London) 276:841–844, 1978Google Scholar
  17. 17.
    Ciosek CP, Ortel RW, Thanassi NM, Newcombe DS: Inhibition of phosphodiesterase by non steroidal anti-inflammatory drugs. Nature (London) 251:148–150, 1974Google Scholar
  18. 18.
    Webb DR, Osheroff PL: Antigen stimulation of prostaglandin synthesis and control of immune responses. Proc Natl Acad Sci USA 73:1300–1309, 1976Google Scholar
  19. 19.
    Goodwin JS, Bankhurst AD, Messner RP: Suppression of human T-cell mitogenesis by prostaglandin. J Exp Med 146:1719, 1977Google Scholar
  20. 20.
    Whisler RL, Newhouse VG: Inhibition of human B lymphocyte colony responses by endogenous synthesized hydrogen peroxide and prostaglandins. Cell Immunol 69:34–45, 1982Google Scholar
  21. 21.
    Eckles DD, Gershwin ME: Pharmacologic and biochemical production of human T-lymphocyte colony formation: Hormonal influences. Immunopharmacology 3:259–274, 1981Google Scholar
  22. 22.
    Goodwin JS, Messner RP, Peake GT: Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. J Clin Invest 62:753–760, 1978Google Scholar
  23. 23.
    Gaut ZN, Baruth H, Randall LO, Ashley C, Paulsrud JR: Stereoisomeric relationships among anti-inflammatory activity, inhibition of platelet aggregation, and inhibition of prostaglandin synthetase. Prostaglandins 10:59–65, 1975Google Scholar
  24. 24.
    Goodwin JS, Messner RP, Williams RC: Inhibitors of T-cell mitogenesis: Effect of mitogen dose. Cell Immunol 45:303–309, 1979Google Scholar
  25. 25.
    Robinson DR, Levine L:In Prostaglandin Synthetase Inhibitors, HJ Robinson, JR Vane (eds). New York, Raven Press, 1974Google Scholar
  26. 26.
    Novagrodsky A, Rubin AL, Stenzel KH: Selective suppression by adherent cells, prostaglandin, and cyclic AMP analogues of blastogenesis induced by different mitogens. J Immunol 122:1–8, 1979Google Scholar
  27. 27.
    Bockman RS: PGE inhibition of T-lymphocyte colony formation. J Clin Invest 64:812–821, 1979Google Scholar
  28. 28.
    Gorski A, Gaciong Z, Dupont B: Enhanced colonability of human T lymphocytes caused by their culturing in vitro. Immunology 44:617–622, 1982Google Scholar
  29. 29.
    Muscoplat CC, Klausner DJ, Brunner CJ, Sloane ED, Johnson DW: Regulation of mitogen- and antigen-stimulated lymphocyte blastogenesis by prostaglandins. Infect Immun 26:311–316, 1979Google Scholar
  30. 30.
    Erten U, Emre T, Cavdar AO, Turker RK: An in vitro study on the effect of prostaglandin E2 and F on E-rosette forming activity on normal lymphocytaes. Prostagland Med 5:255–261, 1980Google Scholar
  31. 31.
    Venza-Teti D, Misefari A, Sofo V, Fimiani V, LaVia MF: Interaction between prostaglandins and human T lymphocytes: Effect of PGE2 on E-receptor expression. Immunopharmacology 2:165–171, 1980Google Scholar
  32. 32.
    Gordon D, Bray M, Morley J: Control of lymphokine secretion by prostaglandins. Nature 262:401–407, 1976Google Scholar
  33. 33.
    Baker PE, Fahey JV, Munck A: Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol 61:52–57, 1981Google Scholar
  34. 34.
    Rappaport RS, Dodge GR: Prostaglandin E inhibits the production of human interleukin 2. J Exp Med 155:943–948, 1982Google Scholar
  35. 35.
    Soppi E, Eskola J, Ruuskanen O: Effects of indomethacin on lymphocyte proliferation, suppressor cell function, and leukocyte migration inhibitory factor (LMIF) production. Immunopharmacology 4:236–242, 1982Google Scholar
  36. 36.
    Darrow TL, Tomar RH: Prostaglandin-mediated regulation of the mixed lymphocyte culture and generation of cytotoxic cells. Cell Immunol 65:172–178, 1980Google Scholar
  37. 37.
    Leung KH, Mihich E: Prostaglandin modulation of development of cell-mediated immunity in culture. Nature 288:597–603, 1980Google Scholar
  38. 38.
    Van Epps D: Suppression of human lymphocyte migration by PGE2. Inflammation 5:81–87, 1981Google Scholar
  39. 39.
    Hopkins J, McConnell I, Pearson JD: Lymphocyte traffic through antigen-stimulated lymph nodes. Immunology 42:225–231, 1981Google Scholar
  40. 40.
    Tilden AB, Balch CM: A comparison of PGE2 effects on human suppressor cell function and on interleukin 2 function. J Immunol 129:2469–2473, 1982Google Scholar
  41. 41.
    Chouaib S, Fradelizi D: The mechanism of inhibition of interleukin 2 production. J Immunol 129:2463–2468, 1982Google Scholar
  42. 42.
    Wolf M, Droege W: Inhibition of cytotoxic responses by prostaglandin E2 in the presence of interleukin 2. Cell Immunol 72:286–293, 1982Google Scholar
  43. 43.
    Schultz RM, Stoychkov JN, Pavlidis N, Chirigos MA, Olkowski ZL: Role of E-type prostaglandin in the regulation of interferon-treated macrophage cytotoxic activity. J Reticuloendothel Soc 26:93–100, 1979Google Scholar
  44. 44.
    Brunda MJ, Herberman RB, Holden HT: Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 124:2682–2688, 1980Google Scholar
  45. 45.
    Garovoy MR, Strom RB, Kaliner M, Carpenter CB: Antibody-dependent lymphocyte mediated cytotoxicity mechanism and modulation by cyclic nucleotides. Cell Immunol 20:197–205, 1975Google Scholar
  46. 46.
    Trofatter KF, Daniels CA: Interaction of human cells with prostaglandins and cyclic AMP modulators. I. Effects on complement-mediated lysis and antibody-dependent cell-mediated cytolysis of herpes-simplex virus-infected human fibroblasts. J Immunol 122:1363–1370, 1979Google Scholar
  47. 47.
    Droller MJ, Schneider MU, Perlmann P: A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell Immunol 39:165–172, 1978Google Scholar
  48. 48.
    Targan S: The dual interaction of prostaglandin E2 (PGE2) and interferon (IFN) on NK lytic activation: enhanced capacity of effector-target lytic interactions (recycling) and blockage of pre-NK cell recruitment. J Immunol 127:1424–1430, 1981Google Scholar
  49. 49.
    Kingston A, Kay JE, Ivanyi J: The effect of prostaglandin E2 and I2-analogues on mitogen induced lymphocyte stimulation. Int J Immunopharmacol 2:243–250, 1980Google Scholar
  50. 50.
    Gordon D, Henderson DC, Westwick J: Effects of prostaglandins E2 and I2 on human lymphocyte transformation in the presence and absence of inhibitors of prostaglandin biosynthesis. Br J Pharmacol 67:17–20, 1979Google Scholar
  51. 51.
    Kelly JP, Johnson MC, Parker CW: Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: Possible role of thromboxanes and products of the lipoxygenase pathway. J Immunol 122:1563–1559, 1979Google Scholar
  52. 52.
    Leung K, Mihich E: Modulation of cell-mediated immunity of prostaglandin synthesis. Int J Immunopharmacol 2:244–249, 1980Google Scholar
  53. 53.
    Gordon D, Novri A, Thomas R: Selective inhibition of thromboxane biosynthesis in human blood mononuclear cells and the effects on mitogen-stimulated lymphocyte proliferation. Immunology 42:472–478, 1981Google Scholar
  54. 54.
    Gualde N, Rabinovitch H, Fredon M, Rigaud M: Effects of 15-hydroperoxyeicosatetranoic acid on human lymphocyte sheep erythrocyte rosette formation and response to concanavalin A associated with HLA system. Eur J Immunol 12:773–777, 1982Google Scholar
  55. 55.
    Goetzl E, Payan DG, Goetzl EJ: Specific suppression of human T lymphocyte function by leukotriene B4. J Immunol 131:551–553, 1983Google Scholar
  56. 56.
    Kennedy MS, Stobo JD, Goldyne ME: In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells. Prostaglandins 20:135–141, 1980Google Scholar
  57. 57.
    Kurland JI, Bockman R: Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J Exp Med 147:952–960, 1978Google Scholar
  58. 58.
    Webb DR, Nowowiejski I: Mitogen-induced changes in lymphocyte prostaglandin levels: A signal for the induction of suppressor cell activity. Cell Immunol 41:72–78, 1978Google Scholar
  59. 59.
    Passwell JH, Dayer JM, Merler E: Increased prostaglandin production by human monocytes after membrane receptor activation. J Immunol 123:115–121, 1979Google Scholar
  60. 60.
    Humes JL, Bonney RJ, Pelus L, Dahlgren ME, Sadowski SJ, Kuehl FA, Davies P: Macrophages synthesise and release prostaglandins in response to inflammatory stimuli. Nature 269:149–155, 1977Google Scholar
  61. 61.
    Ellner JJ, Spagnvolo PJ: Suppression of antigen and mitogen induced human T lymphocyte DNA synthesis by bacterial lipopolysaccharide; mediation by monocyte activation and production of prostaglandins. J Immunol 123:2689–2695, 1979Google Scholar
  62. 62.
    Fuse A, Mahmud I, Kuwata T: Mechanism of stimulation by interferon of prostaglandin synthesis in human cell lines. Cancer Res 42:3209–3214, 1982Google Scholar
  63. 63.
    Bonney RJ, Naruns PP, Davies P, Humes JL: Antigen-antibody complexes stimulate the synthesis and release of prostaglandins by mouse peritoneal macrophages. Prostaglandins 18:605–610, 1979Google Scholar
  64. 64.
    Catanzaro A: Suppressor cells in coccidiomycosis. Cell Immunol 64:235–245, 1981Google Scholar
  65. 65.
    Kaneene J, Anderson R, Johnson DW, Muscoplat CC: Brucella antigen preparations for in vitro lymphocyte immunostimulation assays for bovine Brucellosis. Infect Immun 22:486–491, 1978Google Scholar
  66. 66.
    Dore-Duffy P, Zurier RB: Lymphocyte adherence in multiple sclerosis. Role of monocytes and ancreased sensitivity of MS lymphocytes to prostaglandin E. Clin Immunol Immunopathol 19:303–309, 1981Google Scholar
  67. 67.
    Wolinsky S, Goodwin JS, Messner RP, Williams RC Jr: Role of prostaglandin in the depressed cell-meciated immune response in rheumatoid arthritis. Clin Immunol Immunopathol 17:31–36, 1980Google Scholar
  68. 68.
    Panayi GS, Corrigal V, Youlten LJF: Immunoregulation in the rheumatic diseases. Scand J Rheumatol 38:9–15, 1981Google Scholar
  69. 69.
    Chinen Y, Nagaoka K, Sakurami T, Imura H: Depression of lymphocyte blastogenesis in steroid-treated rheumatoid arthritis. Arthr Rheum 25:713–717, 1982Google Scholar
  70. 70.
    Seitz M, Deimann W, Gram N, Hunstein W, Gemsa D: Characterization of blood mononuclear cells of rheumatoid arthritis patients. Clin Immunol Immunopathol 25:405–416, 1982Google Scholar
  71. 71.
    Scott PA, Farrell JP: Experimental cutaneous leishmaniasis. J Immunol 127:2395–2400, 1981Google Scholar
  72. 72.
    Garin EH, Barratt TM: Effect of indomethacin on lymphocyte response to mitogens in puromycin aminonucleoside nephrosis in the rate. Clin Exp Immunol 49:639–644, 1982Google Scholar
  73. 73.
    Kleinhenz ME, Ellner JJ, Spagnuolo PJ, Daniel TM: Suppression of lymphocyte responses by tuberculous plasma and mycobacterial arabinogalactan. J Clin Invest 68:153–162, 1981Google Scholar
  74. 74.
    Phung ND, Davidson PT: Increased suppressor cell activity in a patient with mycobacterium avium-intracellular pulmonary disease and hypogammaglobulinemia. Ann Allergy 46:204–207, 1981Google Scholar
  75. 75.
    Mason UG, Grenberg LE, Yen SS, Kirkpatrick CH: Indomethacin-response mononuclear cell dysfunction in “atypical” mycobacteriosis. Cell Immunol 71:54–65, 1982Google Scholar
  76. 76.
    Koster F, Williams J, Goodwin JS: Specific immunologic unresponsiveness in disseminated Q fever; Participation of a T cell-monocyte suppressor circuit. Submitted for publication, 1983Google Scholar
  77. 77.
    Kierszenbaum F: Immunologic deficiency during experimental Chagas' disease (trypanosoma cruzi infection). J Immunol 129:2202–2205, 1982Google Scholar
  78. 78.
    Piessens WF, Partono F, Hoffman SL, Ratiwayanto S, Piessens PW, Palmieri JR, Koiman I, Dennis DT, Carney WP: Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. N Engl J Med 307(3):144–148, 1982Google Scholar
  79. 79.
    Goodwin JS, DeHoratius R, Israel H, Peake GT, Messner RP: Suppressor cell function in sarcoidosis. Ann Intern Med 90:169–175, 1979Google Scholar
  80. 80.
    Rice L, Laughter A, Twomey J: Three suppressor systems in human blood that modulate lymphoproliferation. J Immunol 122:991–999, 1979Google Scholar
  81. 81.
    Drysdale B, Shin HS: Activation of macrophages for tumor cell cytotoxicity: Identification of indomethacin sensitive and insensitive pathways. J Immunol 127:760–765, 1981Google Scholar
  82. 82.
    Zighelbolm J, Lichtenstein A, Benjamin D: Response of normal subjects to mitogens: Influence of adherent cells. Clin Immunol Immunopathol 19:406–415, 1981Google Scholar
  83. 83.
    Metzger A, Hoffeld J, Oppenheim J: Macrophage mediated suppression. J Immunol 124:983–988, 1980Google Scholar
  84. 83a.
    Lapp WS, Mendes M, Kirchner H, Gemsa D: Prostaglandin synthesis by lymphoid tissue of mice experiencing a graft-versus-host reaction. Cell Immunol 50:271–281, 1980Google Scholar
  85. 84.
    Hopkins J, McConnell I, Raniwalla J: Antigen-induced non-specific suppressor factor in sheep efferent lymph is prostaglandin E2. Immunology 43:205–210, 1981Google Scholar
  86. 85.
    Thomas JM, Caruer FM, Haisch CE, Fahrenbruch G, Deepe RM, Thomas FT: Suppressor cells in rheusus monkeys treated with antithymocyte globulin. Transplantation 34:83–89, 1982Google Scholar
  87. 86.
    Staszak CS, Goodwin JS, Troup GM, Pathak DR, Williams RC Jr: Decreased sensitivity to prostaglandin and histamine in lymphocytes from normal HLA-B12 individuals: A possible role in autoimmunity. J Immunol 125:181–188, 1980Google Scholar
  88. 87.
    Kirby PJ, Morley J, Ponsford JR, MacDonald WI: Defective PGE reactivity in leucocytes of multiple sclerosis patients. Prostaglandins 11:621–626, 1976Google Scholar
  89. 88.
    Goodwin JS, Messner RP: Prostaglandin E inhibition of mitogen stimulation in patients with multiple sclerosis. Prostaglandins 15:281–287, 1978Google Scholar
  90. 89.
    Dore-Duffy P, Zurier RB: Lymphocyte adherence in multiple sclerosis: Effect of aspirin. J Clin Invest 63:154–159, 1979Google Scholar
  91. 90.
    Page RC, Clagett JA, Engel LD, Wilde G, Sims T: Effects of prostaglandin on the antigen- and mitogen-driven responses of peripheral blood lymphocytes from patients with adults and juvenile periodonitis. Clin Immunol Immunopath 11:77–82, 1978Google Scholar
  92. 91.
    Goodwin JS, Messner RP: Sensitivity of lymphocytes to prostaglandin E2 increases in subjects over age 70. J Clin Invest 64:434–440, 1979Google Scholar
  93. 92.
    Goodwin JS: Changes in lymphocyte sensitivity to prostaglandin E, histamine, hydrocortisone and x-irradiation with age: Studies in a healthy elderly population. Clin Immunol Immunopathol 25:243–251, 1982Google Scholar
  94. 93.
    Goodwin JS: Increased sensitivity to prostaglandin E2 in old people. Prostagland Med 3:395–401, 1979Google Scholar
  95. 94.
    Delfraissy JF, Garanand P, Wallon C, Balavoine JF, Dormont J: Abolished in vitro antibody response in elderly: Exclusive involvement of prostaglandin-induced T suppressor cells. Clin Immunol Immunopathol 24:377–385, 1982Google Scholar
  96. 95.
    Ceuppens J, Goodwin JS: Endogenous prostaglandin E enhances polyclonal immunoglobulin production by tonically inhibiting T suppressor cell activity. Cell Immunol 70:41–54, 1982Google Scholar
  97. 96.
    Goldberg EH, Frikke MJ: The role of suppressor cells in the fetal escape of maternal immunologic rejection.In Suppressor Cells in Human Diseases, JS Goodwin (ed). New York, Marcel Dekker, 1982Google Scholar
  98. 97.
    Olding LB, Benirschke K, Oldstone M: Inhibition of mitosis of lymphocytes from human adults by lymphocytes from human newborns. Clin Immunol Immunopathol 3:79–88, 1974Google Scholar
  99. 98.
    Olding LB, Oldstone M: Thymus-derived peripheral lymphocytes from human newborns inhibit division of their mother's lymphocytes. J Immunol 116:682–687, 1976Google Scholar
  100. 99.
    Johnsen S, Olding LB, Westberg NG, Wilhelmsson L: Strong suppression by mononuclear leukocytes from human newborns on material leukocytes: Mediation by prostaglandins. Clin Immunol Immunopathol 23:606–615, 1982Google Scholar
  101. 100.
    Godwin JS, Messner RP, Peake GT: Increased sensitivity of maternal lymphocytes of PGE2. Clin Res 26:514A, 1978Google Scholar
  102. 101.
    Vanderbeeken Y, Vlieghe MP, Delespesse G: Regulation of the lymphocyte response to phytohemagglutinin during pregnancy: Role of adherent cells and prostaglandins. Am J Reprod Immunol 1:233–235, 1981Google Scholar
  103. 102.
    Goodwin JS, Bromberg S, Staszak C, Kaszubowski PA, Messner RP, Neal JF: Effect of physical stress on sensitivity of lymphocytes to inhibition by prostaglandin E2. J Immunol 127:518–522, 1981Google Scholar
  104. 103.
    Wang BS, Heacock EH, Mannick JA: Characterization of suppressor cells generated in mice after surgical trauma. Clin Immunol Immunopathol 24:161–170, 1982Google Scholar
  105. 104.
    Hasler F, Bluestein HG, Zvaifler NJ, Epstein LB: Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. J Immunol 131:768–772, 1983Google Scholar
  106. 105.
    Kelly RH, Miller DH, Rodnan GP, Hagmann J: Prostaglandin-mediated inhibition of lymphokine secretion in normal individuals and patients with progressive systemic sclerosis (scleroderma, PSS). Agents Actions 12:471–477, 1982Google Scholar
  107. 106.
    Taffet S, Russell SW: Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E. J Immunol 126:424–429, 1981Google Scholar
  108. 107.
    Goodwin JS, Bankhurst AD, Murphy S, Selinger DS, Messner RP, Williams RC Jr: Partial reversal of the cellular immune defect in common variable immunodeficiency with indomethacin. J Clin Lab Immunol 1:197–204, 1978Google Scholar
  109. 108.
    Muscoplat CC, Rakich PM, Thoen CO, Johnson DW: Enhancement of lymphocyte blastogenic and delayed hypersensitivity skin responses by indomethacin. Infect Immun 20:627–632, 1978Google Scholar
  110. 109.
    Lipsmeyer E: Effect of cimetidine and indomethacin on delayed hypersensitivity. Transplantation 33:107–113, 1982Google Scholar
  111. 110.
    Anderson CB, Jaffee BM, Graff RJ: Prolongation of murine skin allografts by prostaglandin E1. Transplantation 23:444–449, 1977Google Scholar
  112. 111.
    Blyth WA, Hill TJ, Field HJ, Harbour DA: Reactivation of herpes simplex virus infection of prostaglandins. J Gen Virol 33:547–551, 1976Google Scholar
  113. 112.
    Tracey DE, Adkinson NF: Prostaglandin synthesis inhibitors potentiate the BCG-induced augmentation of natural killer cell activity. J Immunol 125:136–141, 1980Google Scholar
  114. 113.
    Goodwin JS, Selinger DS, Messner RP, Reed WP: Effect of indomethacin in vivo on humoral and cellular immunity in humans. Infect Immun 19:430–437, 1978Google Scholar
  115. 114.
    Grohmann P, Porzsolt F, Quirt I, Miller R, Phillips R: Stimulation of human NK cell activity by cultured cells. Clin Exp Immunol 44:611–614, 1981Google Scholar
  116. 115.
    Palmer DG, Barbezat GO, Gibbins BL, Grennan DM, Lum J, Myers DB, Wilson K: A single-blind crossover trial of the anti-inflammatory drug sodium meclofenamate and placebo, including an evaluation of hand grip and of lymphocyte responsiveness. Curr Med Res Opin 7:359–367, 1981Google Scholar
  117. 116.
    Goodwin JS, Ceuppens JL, Rodriguez MA: Effect of nonsteroidal antiinflammatory agents on immunologic function in patients with rheumatoid arthritis. J Am Med Assoc (in press), 1983Google Scholar
  118. 117.
    Palmer DG, Ferry DG, Gibbins DL, Hall SM, Grennan DM, Lum J, Myers DB: Ibuprofen and diflunisal in rheumatoid arthritis: A double blind comparative trial. New Zeal Med J 2:45–48, 1982Google Scholar
  119. 118.
    Bach MA, Fournier C, Bach JF: Regulation of theta-antigen expression by agents altering cyclic AMP level and by thymic factor. Ann NY Acad Sci 249:316–320, 1975Google Scholar
  120. 119.
    Gualde N, Rigaud M, Bach JF: Stimulation of prostaglandin synthesis by the serum thymic factor (FTS). Cell Immunol 70:362–367, 1982Google Scholar
  121. 120.
    Rinaldi-Garaci C, Gobbo V, Favalli C, Garaci E, Bistoni F, Jaffe B: Induction of serum thymic-like activity in adult thymoctamized mice by a synthetic analog of PGE2. Cell Immunol 72:97–101, 1982Google Scholar
  122. 121.
    Burchiel SW, Warner NL: Cyclic AMP modulation of Fc receptor expression on a pre-B cell lymphoma. J Immunol 124:1016–1021, 1980Google Scholar
  123. 122.
    Offner H, Danneskiold-Samsoe B, Dore-Duffy P: Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis. Clin Immunol Immunopathol 22:159–165, 1982Google Scholar
  124. 123.
    Stobo JD, Kennedy MS, Goldyne ME: Prostaglandin E modulation of the mitogenic response of human T cells. J Clin Invest 64:1188–1192, 1979Google Scholar
  125. 124.
    Gualde N, Goodwin JS: Effects of prostaglandin E2 and preincubation on lectin-stimulated proliferation of human T cell subsets. Cell Immunol 70:373–378, 1982Google Scholar
  126. 125.
    Kendall R, Targan S: The dual effect of prostaglandin and ethanol on the natural killer cytolytic process. J Immunol 125:2770–2777, 1980Google Scholar
  127. 126.
    Schultz RM, Pavlidis NA, Stylos WA, Chirigos MA: Regulation of macrophage tumoricidal function: A role for prostaglandins of the E series. Science 202:320–327, 1978Google Scholar
  128. 127.
    Drysdale BE, Shin HS: Activation of macrophages for tumor cell cytotoxicity: Identification of indomethacin sensitive and insensitive pathways. J Immunol 127:760–766, 1981Google Scholar
  129. 128.
    McCarthy ME, Zwilling BS: Differential effects of prostaglandins on the antitumor activity of normal and BCG-activated macrophages. Cell Immunol 60:91–97, 1981Google Scholar
  130. 129.
    Schnyder J, Dewald B, Baggiolini M: Effects of cyclooxygenase inhibitors and prostaglandin E2 macrophage activation in vitro. Prostaglandins 22:411–416, 1979Google Scholar
  131. 130.
    Razin E, Bauminger S, Globerson A: Effect of prostaglandins on phagocytes of sheep erythrocytes by mouse peritoneal macrophages. J Reticuloendothel Soc 23:237–242, 1978Google Scholar
  132. 131.
    Razin E, Bauminger S, Globerson A: J Reticuloendothel Soc 23:237–244, 1978Google Scholar
  133. 132.
    Wahl LM, Olsen CE, Wahl SM,et al Prostaglandin and cyclic AMP regulation of macrophage involvement in connective tissue destruction. Ann NY Acad Sci 332:271–278, 1979Google Scholar
  134. 133.
    Smith JW, Steiner AL, Parker CW: Human lymphocytic metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin. J Clin Invest 50:442–449, 1971Google Scholar
  135. 134.
    Melmon KL, Bourne HR, Weinstein Y, Shearer GM, Kram J, Bauminger S: Separation of specific antibody-forming mouse cells by their adherence to insolubilized endogenous hormones. J Clin Invest 53:22–27, 1974Google Scholar
  136. 135.
    Goodwin JS, Wiik A, Lewis M, Bankhurst AD, Williams RC: High affinity binding sites for prostaglandin E on human lymphocytes. Cell Immunol 43:150–159, 1979Google Scholar
  137. 136.
    Kalmar L, Gergely P: Enhancement of mitogen-induced lymphocyte proliferation after preincubation is due to altered sensitivity to prostaglandins. Immunol Lett 4:179–183, 1982Google Scholar
  138. 137.
    Goodwin JS, Bromberg S, Messner RP: Studies on the cyclic AMP response to prostaglandin in human lymphocytes. Cell Immunol 60:298–307, 1981Google Scholar
  139. 138.
    Webb DR, Rogers TJ, Ong S, Steiner A: Detection of prostaglandin induced antigen-stimulated changes in splenic AMP levels by immunofluorescence. Prostagland Med 5:141–147, 1980Google Scholar
  140. 139.
    Morito T, Bankhurst AD, Williams RC Jr: Studies on the modulation of immunoglobulin production by prostaglandins. Prostaglandins 20:383–390, 1980Google Scholar
  141. 140.
    Moretta L, Webb SR, Grossi CE, Lydyard PM, Cooper MD: Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T-cells bearing receptors for IgM or IgG. J Exp Med 146:194–199, 1977Google Scholar
  142. 141.
    Goodwin JS, Kaszubowski PA, Williams RC Jr: Cyclic adenosine monophosphate response to prostaglandin E2 in subpopulations of human lymphocytes. J Exp Med 150:1260–1267, 1979Google Scholar
  143. 141a.
    Ceuppens JL, Goodwin JS: Non-steroidal anti-inflammatory agent inhibit the synthesis of IgM rheumatoid factor in vitro. Lancet 1:528–533, 1982Google Scholar
  144. 142.
    Rodriguez MA, Ceuppens JL, Goodwin JS: Regulation of IgM rheumatoid factor production in lymphocyte cultures from young and old subjects. J Immunol 128:2422–2428, 1982Google Scholar
  145. 143.
    Tosato G, Steinberg AD, Blaese RM: Defective EB virusspecific suppressor cell function in rheumatoid arthritis. N Engl J Med 305:1238–1244, 1981Google Scholar
  146. 144.
    Hasler F, Bluestein H, Zvaifler N, Epstein L: Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. J Exp Med 157:173–185, 1983Google Scholar
  147. 145.
    Goodwin JS: Do non-steroidal anti-inflammatory agents slow the progression of rheumatoid arthritis? Postgrad Med 74:23–31, 1983Google Scholar
  148. 146.
    Hallgren HM, Yunis EJ: Suppressor lymphocytes in young and aged humans. J Immunol 118:1004–1009, 1977Google Scholar
  149. 147.
    Kishimoto S, Tomino S, Mitsuya H, Fukiwara H: Age-related changes in suppressor cell functions of human T-cells. J Immunol 123:1586–1591, 1979Google Scholar
  150. 148.
    Panayi GS, Staite ND, Unger A: Indomethacin inhibits in vitro immunoglobulin production by human B lymphocytes. Agents Actions 11:608–610, 1981Google Scholar
  151. 149.
    Lydyard PM, Brostoff J, Hudspith B, Parry H: Prostaglandin E2-mediated enhancement of human plasma cell differentiation. Immunol Lett 4:113–116, 1982Google Scholar
  152. 150.
    Staite ND, Panayi GS: Regulation of human immunoglobulin production in vitro by prostaglandin E2. Clin Exp Immunol 49:115–122, 1982Google Scholar
  153. 151.
    Cook R: Regulation of the in vitro anamnestic antibody response by cyclic AMP. II. Prostaglandins of the E series. Cell Immunol 40:128–133, 1978Google Scholar
  154. 152.
    Wiedner KJ, Webb DR: The effect of prostaglandin metabolism on immunoglobulin and antibody production in naive and educated whole spleen cells. Prostagland Med 7:79–90, 1981Google Scholar
  155. 153.
    Zimecki M, Webb DR: The regulation of the immune response to T-independent antigens by prostaglandins and B cells. J Immunol 117:2158–2164, 1976Google Scholar
  156. 154.
    Mattingly JA, Kemp JD: Suppression of secondary plaqueforming cell responses by rat splenic adherent cells; Evidence for dependence on prostaglandin production. Cell Immunol 48:195–201, 1979Google Scholar
  157. 155.
    Webb DR, Nowowiejski I: The role of prostaglandins in the control of the primary immune response to sRBC. Cell Immunol 33:1–10, 1977Google Scholar
  158. 156.
    Kurland JI, Kincade PW, Moore MAS: Regulation of Blymphocyte clonal proliferation by stimulatory and inhibitory macrophage-derived factors. J Exp Med 146:1420–1427, 1977Google Scholar
  159. 157.
    Gmelig-Myerling F, Waldmann T: Human B cell activation in vitro: Augmentation and suppression by monocytes of the immunoglobulin production induced by various B-cell stimulants. J Immunol 126:529–536, 1981Google Scholar
  160. 158.
    Rojo JM, Barasoain I, Portoles A: Further studies on the immunosuppressive effects of indomethacin. Int J Clin Pharmacol Ther Toxicol 19:220–222, 1981Google Scholar
  161. 159.
    Rogers TJ, Nowowiejski I, Webb DR: Partial characterization of a prostaglandin-induced suppressor factor. Cell Immunol 50:82–89, 1980Google Scholar
  162. 160.
    Fischer A, Durandy A, Griscelli C: Role of prostaglandin E2 in the induction of nonspecific T lymphocyte suppressor activity. J Immunol 126:1452–1455, 1981Google Scholar
  163. 161.
    Kaszubowski P, Goodwin JS: Monocyte-produced prostaglandin induces Fc gamma receptor expression on human T cells. Cell Immunol 68:343–349, 1982Google Scholar
  164. 162.
    Shimamura T, Hashimoto K, Sasaki S: Feedback suppression of the immune response in vivo. Cell Immunol 68:104–113, 1982Google Scholar
  165. 163.
    Goodwin JS: Modulation of concanavalin A-induced suppressor cell activation by prostaglandin E2. Cell Immunol 49:421–425, 1980Google Scholar
  166. 164.
    Skoldstam L, Zoschke D, Messner R: Increase in con A-induced suppressor cell activity after indomethacin treatment. Arthr Rheum 25:357–359, 1982Google Scholar
  167. 165.
    Skoldstam L, Zoschke D, Messner R: Contrasting effects of prostaglandin E2 and indomethacin in modulating Con A-induced human lymphocyte proliferation and suppressor cell development. Clin Immunol Immunopathol 25:32–42, 1982Google Scholar
  168. 166.
    Badger AM, Griswold DE, Walz DT: Augmentation of concanavalin A-induced immunosuppression by indomethacin. Immunopharmacology 4:149–162, 1982Google Scholar
  169. 167.
    Durandy A, Fischer A, Griscelli C: Dysfunctions of pokeweed mitogen-stimulated T and B lymphocyte responses induced by gammaglobulin therapy. J Clin Invest 67:867–877, 1981Google Scholar
  170. 168.
    Fischer A, Munnich A, Saudubray M,et al. Biotin responsive immunoregulatory dysfunction in multiple carboxylase deficiency. J Clin Immunol 2:35–38, 1982Google Scholar
  171. 169.
    Beer DJ, Rosenwasser L, Dinaxello C, Rocklin R: Cellular interactions in the generation and expression of histamine-induced suppressor activity. Cell Immunol 69:101–112, 1982Google Scholar
  172. 170.
    Rocklin RE, Kiselis I, Beer DJ, Rossi P, Maggi F, Bellanti J: Augmentation of prostaglandin and thromboxane production in vitro by monocytes exposed to histamine-induced suppressor factor. Cell Immunol 77:92–98, 1983Google Scholar
  173. 171.
    Pelus C, Bockman R: Increased prostaglandin synthesis by microphages from tumor bearing mice. J Immunol 123:2118–2124, 1979Google Scholar
  174. 172.
    Glaser M: Indomethacin-sensitive suppressor cells regulate the cell-mediated cytotoxic response to SV 40-induced tumor-associated antigens in mice. Eur J Immunol 10:489–496, 1980Google Scholar
  175. 173.
    Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC Jr: Prostaglandin-producing suppressor cells in Hodgkin's disease. N Engl J Med 197:263–269, 1977Google Scholar
  176. 174.
    Bockman RS: Stage dependent reduction in T-colony formation in Hodgkin's disease. J Clin Invest 66:523–531, 1980Google Scholar
  177. 175.
    DeShazo RP: Indomethacin-responsive mononuclear cell dysfunction in Hodgkin's disease. Clin Immunol Immunopathol 17:66–72, 1980Google Scholar
  178. 176.
    Sibbitt WL, Bankhurst AD, Williams RC Jr: Studies of cell subpopulations mediating mitogen hyporesponsiveness in patients with Hodgkin's disease. J Clin Invest 61:55–63, 1978Google Scholar
  179. 177.
    Johnsen SA: Prostaglandin Associated Immunosuppression, Doctoral thesis. Gateborg, Sweden, University of Gateborg, 1983Google Scholar
  180. 178.
    Bankhurst AD, Kauffman G, Goodwin JS, Williams RC Jr: Suppressor leukocytes in anergic patients with solid tumors. J Lab Clin Immunol 3:3–10, 1980Google Scholar
  181. 179.
    Vosixa G, Thies J: Effect of indomethacin on blastogenesis of lymphocytes from cancer patients: Differentiation of patient types. Clin Immunol Immunopathol 13:30–36, 1979Google Scholar
  182. 180.
    Maca RD, Panje W: Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre and post irradiation therapy. Cancer 50:438–489, 1982Google Scholar
  183. 181.
    Balch CM, Dougherty PA, Tilden A: Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Ann Surg 196:645–650, 1982Google Scholar
  184. 182.
    Braun DP, Harris JE: Relationship of leukocyte numbers, immunoregulatory cell function, and phytohemagglutinin responsiveness in cancer patients. J Natl Cancer Inst 67:809–814, 1981Google Scholar
  185. 183.
    Klein DC, Raisl LG: Prostaglandins: Stimulation of bone resorption in tissue culture. Endocrinology 86:1436–1443, 1970Google Scholar
  186. 184.
    Bennett A, Del Tacca M, Stamford IF, Zebro T: Prostaglandins from tumor of human large bowel. Br J Cancer 35:881–889, 1977Google Scholar
  187. 185.
    Cummings KB, Robertson RP: Prostaglandin: Increased production by renal cell carcinoma. J Urol 118:720–727, 1977Google Scholar
  188. 186.
    Husby G, Strickland RG, Rigler GL, Peake GT, Williams RC Jr: Direct immunochemical detection of prostaglandin E and cyclic nucleotides in human malignant tumors. Cancer 40:1629–1636, 1977Google Scholar
  189. 187.
    Powles TJ, Coomes RC, Neville AM, Ford HT, Gazet JC, Levine L: 15-keto-13, 14 dihydroprostaglandin E2 concentrations in serum of patients with breast cancer. Lancet 2:138–143, 1977Google Scholar
  190. 188.
    Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64:1061–1068, 1980Google Scholar
  191. 189.
    Sykes JAX, Maddox JS: Prostaglandin production by experiment tumorus and effects of anti inflammatory compounds. Nature New Biol 237:59–65, 1972Google Scholar
  192. 190.
    Tashjian AH, Voelkel EF, Levine L, Goldhaber P: Evidence that the bone-resorption stimulating factor produced by mouse fibrosarcoma cells in prostaglandin. J Exp Med 136:1329–1336, 1972Google Scholar
  193. 191.
    Owen K, Gomolka D, Droller MJ: Lymphocyte induced production of prostaglandin E2 by tumor cells in vitro: Requirements for direct contact and lymphocyte viability. Cell Immunol 55:428–435, 1982Google Scholar
  194. 192.
    Plescia OJ, Smith AH, Grinwich K: Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci 72:1848–1854, 1975Google Scholar
  195. 193.
    Grinwich KD, Plescia OJ: Tumor-mediated immunosuppression: Prevention by inhibitors of prostaglandin synthesis. Prostaglandins 14:1175–1183, 1977Google Scholar
  196. 194.
    Hial V, Horokova Z, Shaff RE, Beaven MA: Alteration of tumor growth by aspirin and indomethacin: Studies with two transplantable tumors in mice. Curr J Pharmacol 37:367–373, 1976Google Scholar
  197. 195.
    Lynch NR, Casatles M, Astonin M, Salomon JC: Mechanism of inhibition of tumor growth by aspirin and indomethacin. Br J Cancer 38:503–509, 1978Google Scholar
  198. 196.
    Humes JL, Cupo J, Strausser HR: Effects of indomethacin on Moloney sarcoma virus-induced tumors. Prostaglandins 6:463–469, 1974Google Scholar
  199. 197.
    Strausser HR, Humes JL: Prostaglandin synthesis inhibition: Effect on bone changes and sarcoma tumor induction in mice. Int J Cancer 15:724–729, 1975Google Scholar
  200. 198.
    Bennett A, Houghton JK, Leaper DJ, Stanford IF: Cancer growth, response to treatment and survival time in mice: Beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins 17:179–186, 1979Google Scholar
  201. 199.
    Pollard M, Luckert PH: Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 214:558–559, 1981Google Scholar
  202. 200.
    Waddell WR, Gerner RE, Reich MD: Nonsteroid antiinflammatory drugs for desmoid tumors and carcinoma of the stomach. Submitted for publication, 1982Google Scholar
  203. 201.
    Panje WR: Regression of head and neck carcinoma with a prostaglandin synthesis inhibitor. Arch Otolaryngol 107:658–663, 1981Google Scholar
  204. 202.
    Galasko CSB, Bennett A: A relationship of bone distinction in skeletal metastases to osteoclast activation and prostaglandins. Nature 263:508–513, 1976Google Scholar
  205. 203.
    Powles TJ, Clar SA, Easty DM, Easty CG, Neville AM: The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer 28:316–321, 1973Google Scholar
  206. 204.
    Yoneda R, Mundy GR: Prostaglandins are necessary for osteoclast-activating factor production by activated peripheral blood leukocytes. J Exp Med 149:279–288, 1979Google Scholar
  207. 205.
    Lupulescu A: Enhancement of carcinogenesis by prostaglandins in male, albino Swiss mice. J Natl Cancer Inst 61:97–103, 1978Google Scholar
  208. 206.
    Levine L, Ohucki K: Retinoids as well as tumor promoters enhance deacylation of cellular lipids and prostaglandin production in MDCK cells. Nature 276:274–280, 1978Google Scholar
  209. 207.
    Ohuchi K, Levine L: Stimulation of prostaglandin synthesis by tumor-promoting phorbol-12-13-diesters in canine kidney (MDCK) cells. J Biol Chem 253:4783–4790, 1978Google Scholar
  210. 208.
    Yamasaki H, Mufson RA, Weinstein IB: Phorbol esteir induced prostaglandin synthesis and [3H]-TPA metabolism by TPA-sensitive and TPA-resistant friend erythroleukemia cells. Biochem Biophys Res Commun 89:1018–1025, 1979Google Scholar
  211. 209.
    Buick R, Fry S, Salmon S: Effect of host-cell interactions on clonogenic carcinoma cells in human malignant effusions. Br J Cancer 41:695–704, 1980Google Scholar
  212. 210.
    Santoro MG, Philpott GW, Jaffe BM: Inhibition of tumor growth in vivo and in vitro by prostaglandin E. Nature 263:777–779, 1976Google Scholar
  213. 211.
    Stringfellow D, Fitzpatrick F: Prostaglandin Dα controls pulmonary metastasis of malignant melanoma cells. Nature 282:76–84, 1979Google Scholar
  214. 212.
    Favalli C, Garaci E, Etheredge E, Santoro MG, Jaffe BM: Influence of PGE in the immune response in melanomabearing mice. J Immunol 125:897–906, 1980Google Scholar
  215. 213.
    Hofer D, Duibitsky AM, Reilly P, Santoro MG, Jaffe BM: The interactions between indomethacin and cytotoxic drugs in mice bearing B-16 melanomas. Prostaglandins 20:1033–1039, 1980Google Scholar
  216. 214.
    Santoro MG, Jaffe BM: Inhibition of friend erythroleukemia-cell tumors in vivo by a synthetic analogue of prostaglandin E2. Br J Canc 39:408–413, 1979Google Scholar
  217. 215.
    Karmali RA, Horrobin DF, Menenzes J, Patel P: The relationship between concentrations of prostaglandin A1, E1, E2 and E2 alpha and rates of cell proliferation. Pharmacol Res Commun 11:69–76, 1979Google Scholar
  218. 216.
    Klimpel GR: Soluble factors from BCG-induced suppressor cells inhibits in-vitro PFC responses but not cytotoxic responses. Cell Immunol 47:218–224, 1980Google Scholar
  219. 217.
    Klimpel G, Henney CS: BCG-induced suppressor cells. I. Demonstration of a macrophage-like suppressor cell that inhibits cytotoxic T-cell generation in vitro. J Immunol 120:563–570, 1978Google Scholar
  220. 218.
    Klimpel GR, Okada M, Henney CS: Inhibition of in vitro cytotoxic responses by BCG-induced microphage-like suppressor cells II. Suppression occurs at the level of “helper” T cell. J Immunol 123:350–357, 1979Google Scholar
  221. 219.
    Neta R, Slavin SB: Adjuvants in the induction of suppressor cells. Infect Immun 23:360–365, 1979Google Scholar
  222. 220.
    Savary CA, Lotzova E: Suppression of natural killer cell cytotoxicity by splenocytes from corynebacterium parvum-injected bone marrow-tolerant and infant mice. J Immunol 120:239–245, 1978Google Scholar
  223. 221.
    Grimm W, Seitz M, Kirchner H, Gemsa D: Prostaglandin synthesis in spleen cell cultures of mice injected with corynebacterium parvum. Cell Immunol 40:419–426, 1978Google Scholar
  224. 222.
    Wahl SM, Wahl LM, McCarthy JB, Chedid L, Mergenhagen SE: Macrophage activation by mycobacterial water soluble compounds and synthetic maramyl dipeptide. J Immunol 122:2226–2232, 1979Google Scholar
  225. 223.
    Lynch NR, Salomon J: Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst 62:117–121, 1979Google Scholar
  226. 224.
    Droller M, Gomolka D: Interferon expression and prostaglandin synthetase inhibition in the in vitro and in vivo manipulation of immune response expression in an animal model of bladder cancer. Cell Immunol 72:1–13, 1982Google Scholar
  227. 225.
    Droller MA, Gomolka D: Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic-polycytidylic acid. Cancer Res 42:5038–5045, 1982Google Scholar
  228. 226.
    Goodwin JS, Webb DR: Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol 15:106–122, 1980Google Scholar

Copyright information

© Plenum Publishing Corporation 1983

Authors and Affiliations

  • James S. Goodwin
    • 1
  • Jan Ceuppens
    • 2
  1. 1.Department of MedicineUniversity of New Mexico School of MedicineAlbuquerque
  2. 2.Department of MedicineUniversity of LeuvenLeuvenBelgium

Personalised recommendations